If you are attending ESMO Breast Cancer 2025 in Munich, Germany 14-17 May, Kay Yeung, an investigator on the I-SPY clinical protocol will be presenting clinical data regarding our VV1 program in partnership with Regeneron on newly diagnosed breast cancer. Mini oral session presentation number#LBA2 “Rates of Pathologic Complete Response after VV1 and Cemiplimab (Alone and in Treatment Sequence-Strategy) in the Neoadjuvant Setting: Results from the I-SPY 2.2 Trial”, 8:30 AM-10:10 AM, Room 14 on Thursday 15th.
Link to the agenda: ESMO Breast Cancer 2025 – ESMO Breast Cancer 2025 – Onsite and Online Congress
Media Inquiries
For inquiries, please contact mediarelations@vyriad.com